Published 25 days ago • loading... • Updated 25 days ago

New Cancer Drug Breakthrough: 46% of Kidney Cancer Patients Respond to Novel Treatment Combination

Summary by stocktitan.net

Novel drug combination shows promising 46% response rate in advanced kidney cancer trial. Phase 3 study launching soon. See complete efficacy and safety data.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

3 Articles

All

Left

Center

Right

The Standard-Journal

Reposted by

The AI Journal

Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response

HAYWARD, Calif.--(BUSINESS WIRE)--Jun 1, 2025-

25 days ago·Milton, United States

Read Full Article

stocktitan.net

New Cancer Drug Breakthrough: 46% of Kidney Cancer Patients Respond to Novel Treatment Combination

Novel drug combination shows promising 46% response rate in advanced kidney cancer trial. Phase 3 study launching soon. See complete efficacy and safety data.

25 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year